ERBB2 and breast carcinoma: In breast cancer, the cut-off value of the immunohistochemical marker Ki67 has become one of the important prognostic indicators (8), and recently a scoring system combining ER, PR, HER2, and Ki67 has been developed as an auxiliary tool for clinical prognosis management of breast cancer (9).